The faith-based shareholders’ proposal was challenged by UnitedHealth twice, thanks to a recent SEC guidance change the shareholders slammed as unfair. They could still reintroduce it next year.
The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback